1st Biotherapeutics' HPK1 inhibitor FB-849 cleared to enter clinic for advanced solid tumors

Dec. 13, 2022

1st Biotherapeutics Inc. has received clearance from the FDA for its IND application to evaluate FB-849, a small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with advanced solid tumors.

BioWorld Science Cancer Immuno-oncology FDA IND

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 15, 2025.

Illimis $42M series B to spur study of Aβ-clearing fusion protein

BioWorld

Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific...

Circode applies circRNA to heart disease drug R&D, in vivo CAR T

BioWorld

Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...